Tamoxifen Treatment Promotes Phosphorylation of the Adhesion Molecules, P130Cas/BCAR1, FAK and Src, Via an Adhesion-dependent Pathway
Overview
Affiliations
Reports that the adhesion-associated molecule p130Cas/BCAR1 promotes resistance to tamoxifen suggested that adhesion-mediated signalling may be altered by tamoxifen treatment. We find that p130Cas/BCAR1 phosphorylation is enhanced in tamoxifen-treated estrogen receptor (ER)-positive MCF-7 breast cancer cells. The effects of estrogen and tamoxifen were assessed independently and in combination, and the results demonstrate that tamoxifen antagonizes estrogen regulation of p130Cas/BCAR1 phosphorylation. Phosphorylation correlates with tamoxifen ER antagonist effects, as phosphorylation effects are replicated by the pure antiestrogen ICI 182, 780. Correspondingly, phosphorylation is not changed in ER-negative cells exposed to tamoxifen. We show that deletion of the p130Cas/BCAR1 substrate domain substantially reduces tamoxifen-induced phosphorylation of p130Cas/BCAR1 and confers enhanced sensitivity to tamoxifen. P130Cas/BCAR1 forms a phosphorylation-dependent signalling complex with focal adhesion kinase (FAK) and Src kinase that promotes adhesion-mediated cell survival. Therefore, we examined the kinetics of p130Cas/BCAR1, Src and FAK phosphorylation over a 14-day time course and find sustained phosphorylation of these molecules after 7 days exposure to tamoxifen. Inhibition of Src kinase is shown to reduce tamoxifen-promoted p130Cas/BCAR1 phosphorylation and reduce cell viability. Stimulation of the Src/FAK/p130Cas/BCAR1 adhesion signalling pathway in tamoxifen-treated MCF-7 cells does not cause increased migration; however, there is Src-dependent phosphorylation of the cell survival molecule Akt. Correspondingly, Akt inhibition reduces cell viability in cells treated with tamoxifen. We propose that prolonged activation of adhesion-dependent signalling may confer a survival advantage in response to additional cellular insults or alternatively, may poise cells to develop a migratory phenotype in response to additional cellular cues.
Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets.
Liu Z, Zhang X, Ben T, Li M, Jin Y, Wang T Biomark Res. 2025; 13(1):38.
PMID: 40045379 PMC: 11884212. DOI: 10.1186/s40364-025-00745-7.
Rees M, Smith C, Barrett-Lee P, Hiscox S Oncotarget. 2021; 11(51):4722-4734.
PMID: 33473257 PMC: 7771710. DOI: 10.18632/oncotarget.27846.
Wilson R, Archid R, Reymond M Int J Mol Sci. 2020; 21(11).
PMID: 32532126 PMC: 7312018. DOI: 10.3390/ijms21114158.
Campbell P, Mavingire N, Khan S, Rowland L, Wooten J, Opoku-Agyeman A J Cell Physiol. 2018; 234(1):108-121.
PMID: 30076704 PMC: 6202151. DOI: 10.1002/jcp.27013.
Rac GTPase regulation of 3D invasion in neuroblastomas lacking MYCN amplification.
Mitchell C, ONeill G Cell Adh Migr. 2016; 11(1):68-79.
PMID: 27224546 PMC: 5308223. DOI: 10.1080/19336918.2016.1183868.